Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Information

Summary of results of operations by segment

(In thousands)			Contract		Corporate		Total
Three Months Ended March 31, 2022	Therapeutics		Research		and Other		Company
Total revenue	$	231	$	4,096	$	(2,874)	$	1,453
Cost of revenue		—		3,854		(2,699)		1,155
Research and development		14,481		—		(175)		14,306
General and administrative		—		840		5,259		6,099
Revaluation of contingent consideration		(1,200)		—		—		(1,200)
Loss from operations	$	(13,050)	$	(598)	$	(5,259)	$	(18,907)
(In thousands)			Contract		Corporate		Total
Three Months Ended March 31, 2021	Therapeutics		Research		and Other		Company
Total revenue	$	242	$	3,200	$	(1,665)	$	1,777
Cost of revenue		—		2,769		(1,567)		1,202
Research and development		7,936		—		(98)		7,838
General and administrative		—		629		4,198		4,827
Revaluation of contingent consideration		16,439		—		—		16,439
Loss from operations	$	(24,133)	$	(198)	$	(4,198)	$	(28,529)